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TWENTY YEARS OF IMMUNOCONTRACEPTIVE RESEARCH:
LESSONS LEARNED
Lowell A. Miller, Ph.D., Kathleen A. Fagerstone, Ph.D., and Douglas C. Eckery, Ph.D.
Abstract: The National Wildlife Research Center (NWRC) began immunocontraception vaccine research by
testing porcine zona pellucida (PZP) on white-tailed deer (Odocoileus virginianus). Early PZP research
demonstrated that PZP induced infertility; however, increased length of the rut was observed in PZP-treated
deer. An alternative vaccine using a keyhole limpet hemocyanin-gonadotropin-releasing hormone (KLH-GnRH)
conjugate formulated with modified Freund’s adjuvant was developed at NWRC. Suppression of GnRH has
reduced reproduction in both sexes but is most effective in females. This vaccine was effective in preventing
contraception in female deer for several years after a prime and boost. Due to adverse side effects of Freund’s
adjuvant, NWRC developed a new adjuvant called AdjuVac, a mineral oil/surfactant adjuvant with the addition of
Mycobacterium avium as an immunostimulant. The price of KLH prompted a search for a more economical
hemocyanin carrier protein for the GnRH peptide. Blue protein, derived from the mollusk Concholepas
concholepas, proved to be a successful option. Formulation improvements resulted in a vaccine that can be
effective as a single injection for multiple years, now called GonaCon. GonaCon is registered with the
Environmental Protection Agency (EPA) for use in white-tailed deer in urban/suburban areas and for wild horses
(Equus caballus) and burros (Equus asinus). Future GonaCon applications may include reducing reproduction to
manage populations of other wildlife species, such as prairie dogs (Cynomys ludovicianus) in urban areas and
suppressing reproduction to reduce the spread of venereal diseases such as brucellosis. Research is being
conducted to develop a GnRH vaccine used in combination with the rabies vaccine to control population growth
in free-roaming dogs, with the secondary effect of managing the spread of rabies. The EPAwould regulate all these
uses. Research is also ongoing on a GnRH vaccine to delay the onset of adrenocortical disease in pet ferrets
(Mustela putorius), a use regulated by the United States Department of Agriculture.
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INTRODUCTION
In 1992, the United States Department of
Agriculture National Wildlife Research Center
(NWRC) began a project to develop reproductive
control methods as an additional nonlethal tool to
manage overabundant wildlife. The early focus of
the project was on white-tailed deer (Odocoileus
virginianus) because stakeholders identified over-
abundant deer populations in urban/suburban
areas as a concern because of increases in deer-
motor vehicle collisions, property damage, and
habitat destruction. The project began by study-
ing porcine zona pellucida (PZP) immunocontra-
ception technology for management of white-
tailed deer.23,47,48 The project’s focus later shifted
to development of vaccines using gonadotropin-
releasing hormone (GnRH) as the antigen for
several reasons: first, the PZP vaccines are only
effective in females and resulted in prolonged
periods of estrus cyclicity because normal repro-
ductive hormones were maintained; second, the
project’s focus broadened beyond white-tailed
deer, and a broadly effective vaccine in most
mammals was wanted that would affect both
sexes; and third, other researchers were develop-
ing PZP vaccines, so duplicate research efforts
needed to be minimized. Initial studies were
conducted with various formulations of GnRH
vaccines. Eventually, the vaccine GonaCon was
developed at NWRC, which suppresses reproduc-
tive hormone production, estrus, and spermato-
genesis in mammals, often after a single injection.
For this review, GonaCon is a GnRH-based
immunocontraceptive vaccine comprised of nu-
merous GnRH peptide molecules coupled to a
mollusk carrier protein (either keyhole limpet
hemocyanin [KLH] or blue protein [Concholepus
concholepus]) mixed with a mineral oil-based
adjuvant containing Mycobacterium avium (Adju-
Vac) and made into an emulsion (Table 1).
Generally, efficacy for longer than 1 yr is achieved
from a single injection, and contraception may be
extended by administering a boost vaccination.48,50
GonaCon proved efficacious in deer, reducing
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Table 1. Formulations for GnRH vaccines tested by the National Wildlife Research Center.
Name of
formulationa Species tested
Mollusk
proteinb Adjuvant usedc
Amount of
M. aviumd Citation
GnRH vaccine White-tailed deer KLH FCA for prime,
FIA for
boost
NA
23, 29, 42, 48
GnRH vaccine White-tailed deer
fawns
KLH FCA, FIA
boost
NA 43
GnRH vaccine Norway rats KLH FA prime; FIA
boost
NA 44
GnRH vaccine New Zealand
white rabbits
KLH FCA; FIA;
AdjuVac
Standard 57
GonaCon White-tailed deer KLH and blue AdjuVac Standard 42
GonaCon Black-tailed deer
(Odocoileus
hemionus)
KLH AdjuVac Standard, one-half
standard, one-
fourth standard
55
GonaCon Elk KLH AdjuVac Standard 22
GonaCon Elk Blue AdjuVac Standard 56
GonaCon Bison KLH AdjuVac Standard 50
GonaCon Domestic swine KLH AdjuVac Standard 51
GonaCon Feral swine KLH AdjuVac Standard 26, 27
GonaCon Wild boar KLH AdjuVac Standard 37
GonaCon California
ground
squirrel
KLH AdjuVac Standard 53
GonaCon Eastern gray
squirrel
Blue AdjuVac Standard 54
GonaCon Black-tailed
prairie dog
Blue AdjuVac Standard 66
GonaCon Domestic cats KLH AdjuVac Standard 32, 34
GonaCon Brushtail possum KLH AdjuVac Standard 8
GonaCon Tammar wallaby;
Gray kangaroo
Blue AdjuVac Standard 60
GonaCon Domestic ferret KLH and blue AdjuVac Standard 40
GonaCon-
Cervid (EPA
registration)
White-tailed deer KLH AdjuVac Standard 13, 14, 21
GonaCon-
Equine (EPA
registration)
Wild horses KLH AdjuVac Standard 24, 25, 28
GonaCon-
Equine (EPA
registration)
Wild horses Blue AdjuVac Standard 18
GonaCon Dogs KLH AdjuVac Standard 19
GonaCon Dogs KLH AdjuVac One-half standard 2
GonaCon-
Canine
(Proposed
EPA
registration)
Dogs Blue AdjuVac One-fourth standard 63
a GonaCon is defined as a GnRH immunocontraceptive vaccine comprised of numerous GnRH protein molecules coupled to a
mollusk carrier protein (either keyhole limpet hemocyanin [KLH] or blue protein) mixed with a mineral oil-based adjuvant
(AdjuVac) and made into a stiff emulsion.
b The EPA registered formulations for GonaCon can contain either keyhole limpet hemocyanin (KLH), or blue protein
(Concholepas concholepas).
c GonaCon is formulated with the adjuvant Adjuvac, a dilution of Mycopar, which contains Mycobacterium avium. FCA,
Freund’s Complete; FIA, Freund’s Incomplete.
d The standard amount of M. avium (approximately 0.17 mg/ml) is the concentration in AdjuVac for the Environmental
Protection Agency (EPA) registered products. NA, not applicable.
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reproductive behaviors in females and reducing
the length of the rut;13,23 it was also found to
induce infertility in many different species of
mammals.9 NWRC has subsequently improved
the manufacturing process for GonaCon to in-
clude aseptic manufacturing in a clean room, as
well as scaling up production to allow GonaCon
to be made in larger batches. An adjuvant
(AdjuVac) was developed by the NWRC to
increase the effectiveness of both PZP and GnRH
vaccines.
This manuscript will briefly describe much of
the research conducted by the NWRC during the
last 20 yr, the vaccines and adjuvant that have
been developed, the changes that have been made
to improve those products, the lessons NWRC
has learned, and what still needs to be determined
after 20 yr of research on immunocontraception in
wildlife.
VACCINE DESIGN FOR DIFFERENT
REPRODUCTIVE SYSTEM TARGETS
Immunocontraceptive vaccines use the animal’s
immune system to produce antibodies against
gamete proteins, reproductive hormones, and
other proteins essential for reproduction.30 The
antibodies interfere with the biologic activity of
the reproductive proteins,61 and depending on the
antigen and formulation, the vaccines can be
effective for 1–4 yr or longer with single or
multiple injections.47,62 Two antigens, PZP and
GnRH, have been used to develop immunocon-
traceptive vaccines for wildlife. The NWRC has
conducted research on both PZP and GnRH
vaccines. The antigen used, including its mode
of action on the reproductive system and the
design of the vaccines, is vital in determining
vaccine efficacy in different mammalian species.
PZP immunocontraceptive vaccines
The NWRC began its contraceptive research
program in 1991 by studying PZP, a combination
of three zona pellucida (ZP) proteins extracted
from pig ovaries, because PZP had previously
been shown to be effective as an antigen in an
immunocontraceptive vaccine used for horses
(Equus caballus).35 In the authors’ early work, it
was effective in coyotes (Canis latrans) as well.38
The PZP vaccine targets the ZP, a glycoprotein
layer located on the outer surface of the egg.
Antibodies to ZP result in infertility either by
blocking sperm from penetrating the ZP layer or
by interfering with egg maturation within the
follicle.6
Extracted PZP proteins were initially provided
to the NWRC by Dr. Bonnie Dunbar (Baylor
College of Medicine, Houston, Texas, 77030,
USA) and Dr. Irwin Liu (University of Califor-
nia-Davis, Davis, California 95616, USA) and
were produced by the method of Dr. Dunbar.7
For later NWRC studies, native PZP and SpayVac
(PZP encapsulated in liposomes) were produced
and provided by Dr. Robert Brown (ImmunoVac-
cine Technologies [IVT], Nova Scotia, B3H OA8
Canada).3
During early research with PZP prepared by the
Dunbar method, 11 white-tailed deer does at
Pennsylvania State University (University Park,
Pennsylvania 16802, USA) received a prime
vaccination in July to August and two boost
vaccinations in September and October; in No-
vember, the does were paddocked with bucks.
Extensive observations of breeding activity by a
team of Penn State students were made compar-
ing the breeding activity of female deer vaccinated
with the vaccine. This PZP preparation was quite
effective in preventing pregnancy when deer
received both prime and boost doses, with 89%
reduction in fawning over a 4-yr period and 76%
over 6 yr.47
After demonstrating that PZP vaccines could
be effective when given as a prime and a boost,
NWRC researchers attempted development of a
vaccine that could induce a long-lasting immune
response after a single injection. A study was
subsequently conducted comparing the effective-
ness of six different single injection vaccine
formulations,41 containing different PZP prepa-
rations (Dunbar preparation, IVT preparation
without liposomes, and SpayVac). The study
demonstrated that the different production
methods for PZP affected the duration of effect
of the resulting vaccines. The PZP isolated by
IVT produced a longer-lasting response as
compared witj the Dunbar PZP isolation meth-
od. The IVT PZP with liposomes (SpayVac) and
without liposomes were the most efficacious
formulations, with 8 of the 10 does in each
group contracepted for 5 to 7 yr after a single
injection.41 The normal fertility level for this
herd was 1.7 fawns/doe per year.42 The deer
study also compared different adjuvants used
with the SpayVac PZP: SpayVac prepared in
AdjuVac; lypophilized SpayVac suspended in
AdjuVac; and SpayVac mixed with alum as the
adjuvant. The water-in-oil emulsion produced
with AdjuVac provided a longer-lasting response
than the alum or suspension.41 NWRC research-
ers were encouraged that vaccines formulated
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with AdjuVac provided the long-lasting efficacy
with a single injection that would be required for
most uses in wildlife.
Because the process of isolating PZP from pig
ovaries obtained from pig slaughterhouse facili-
ties is costly and time consuming, an alternative
source of PZP was sought. In one study,45
different recombinant rabbit ZP proteins pro-
duced in Escherichia coli were studied. The
proteins RC55, RC75a, and RC75b all showed
cross reactivity with native PZP. Deer vaccinated
with these recombinant proteins were compared
with deer vaccinated with native PZP. The native
PZP was much more effective in contracepting
deer than the rabbit recombinant proteins. In
another study,49 the NWRC used selected PZP-
derived peptides (generated by Chiron Mimo-
tope Systems, San Diego, 92121, California)
identified from published sequence information
(National Institutes of Health gene bank, www.
ncbi.nlm.nih.gov/genbank) to identify which
peptide or peptide groups were responsible for
the contraceptive effect. The peptides were
screened using serum from a PZP-treated doe,
and a ZP1 mimitrope (pins 10–16) demonstrated
the greatest response. When this ZP1 peptide
was used to vaccinate a group of nine deer, some
efficacy was observed, but there was also large
variation in the immune response between deer.
The deer with the highest antibody titer to this
ZP1 peptide exhibited three estrous cycles and
had no fawns; however, the average fawning rate
in this group was 0.89 fawns/doe, which was
indicative of a partial contraceptive effect. It was
concluded that the native PZP, which apparently
maintains the natural folding of the glycosylated
protein, was more consistent in inducing infer-
tility than this or any of the other peptides
tested.49
By effectively blocking sperm from penetrating
the egg without reducing circulating hormone
levels, PZP vaccines caused repeated cycling
during the rut season in deer at Penn State
University,23 extending the breeding season for
the PZP-treated deer for up to seven estrus cycles
(x¯ ¼ 2.4 cycles), with a mean of 98 days and a few
deer cycling up to 150 days.47 This increased length
of the breeding season has the potential for
increasing car-deer collisions because of increased
deer movement. It also causes increased energy
expenditures by rutting deer, and if antibody titers
drop below a critical threshold late in the breeding
season, late season fawns can be produced that
may not survive the northern winter climates.
Moreover, other researchers were developing
PZP vaccines,30 so duplication of research efforts
needed to be minimized. For these reasons, the
NWRC discontinued testing of PZP in deer and
focused research on developing an alternative
contraceptive vaccine for use in ungulates.
GnRH immunocontraceptive vaccines
The NWRC researchers desired a vaccine that
would eliminate most reproductive behaviors.
GnRH is a key reproductive hormone that
controls steroidogenesis and gametogenesis by
stimulating the release of gonadotropins from the
pituitary gland, triggering the cascade of repro-
ductive hormones that lead to sperm production
and ovulation. The NWRC began development of
GnRH vaccines in the early 1990s, and the first
GnRH vaccine was tested at Penn State Univer-
sity beginning in 199423,46 (Table 1). This GnRH
vaccine was given to females (n¼8) and males (n¼
4) as a prime injection followed by a boost 1 mo
later. Extensive observations of breeding activity
were made. Fawning rates in the study were 0.21
fawns/doe per year over 4 yr in the treated does
compared with 1.8 fawns/doe per year in control
does. The contraceptive activity was correlated
with the antibody titer for the vaccine, with
fertility returning as the antibody titers dropped.
GnRH-treated does showed no breeding behav-
ior, and bucks had no interest in them; the
reduction in progesterone shown in the GnRH-
treated does suggested that they were not cycling.
GnRH immunized bucks had a significant reduc-
tion in testosterone and had no interest in sexual
activity when paired with control females. De-
pending on the immunization schedule, antlers in
GnRH-treated bucks either dropped early in the
fall or remained in velvet.
After years of refinement, a new vaccine
(GonaCon Immunocontraceptive Vaccine,
NWRC, Fort Collins, Colorado, 80521, USA)
was developed by the NWRC that has been
shown to suppress reproduction in treated
animals of both sexes, can be administered as a
single injection,52 is effective for at least a year in
most mammalian species,9 and is often effective
for multiple years.9 Like earlier GnRH vaccines,
GonaCon stimulates the production of antibod-
ies that neutralize GnRH, suppressing repro-
ductive hormone production (i.e., follicle-
stimulating hormone [FSH] and luteinizing hor-
mone [LH] from the pituitary gland and estradi-
ol, progesterone, and testosterone from the
gonads). The design of GonaCon is the key to
its long-term efficacy with a single injection; the
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characteristics of the design that allow it to be
effective without a boost injection will be
discussed in further detail.
VARIATION IN VACCINE EFFICACY
AMONG INDIVIDUAL ANIMALS
Users of a contraceptive vaccine need to be
aware that, unlike surgical sterilization, which is
100% efficacious, the efficacy of immunocontra-
ceptive vaccines is subject to individual variation,
so it is difficult to predict the percent and
duration of induced infertility. A certain percent-
age of vaccinated animals will always be nonre-
sponders or have a reduced immune response to a
vaccine.59 This is true for both disease vaccines
and PZP and GnRH immunocontraceptive vac-
cines. For human or companion animal vaccines,
it is possible to give an injection and a follow-up
boost that increases the effectiveness of the
vaccine and may provide almost 100% efficacy.
For wildlife or feral animals, a boost injection is
less desirable because the animal must be relo-
cated, it is difficult to individually mark animals,
and it is difficult and time consuming to handle an
animal more than once. A single injection, long-
lasting contraceptive vaccine like GonaCon or
SpayVac is a more attractive wildlife management
tool because animals would need to be handled or
darted less frequently. However, additional stud-
ies and/or population models20,67 will be required
to provide managers with recommendations for
implementing contraceptive programs as manage-
ment tools to reduce or maintain wildlife popula-
tion levels.
Contraceptive vaccine users also need to know
that, while GonaCon is effective in both males
and females, it has been demonstrated to be
effective for a longer period of time in females
than in males. In a GnRH vaccine study at Penn
State University, male deer (n ¼ 5) given a single
injection showed reduced testicular size and
plasma testosterone for at least three breeding
seasons.29,46 Males given two immunizations tend-
ed to remain infertile for an additional 2–3 yr. In
contrast, six of nine female deer were contra-
cepted for 4 to 6 yr after a single injection.41
Similar differences between longevity of vaccine
effectiveness in males and females have been
demonstrated with cats (Felis catus). When a
single injection of GonaCon was given to 15
female cats, 93% of vaccinated cats remained
infertile for the first year, with 73, 53, 40, and 27%
infertile for 2, 3, 4, and 5 yr, respectively. The
median duration of contraception was 39.7 mo
based on suppression of hormone levels.32 In a
similar study with males given a single injection of
GonaCon, 9 of 12 cats responded with high
antibody titers and a drop in testosterone to a
nondetectable range; however, three treated cats
failed to produce a high GnRH titer and showed
no suppression of testosterone.34 The median
duration of effect for the male cats that responded
to the vaccine was 14 mo, with one treated cat
having undetectable testosterone at 34 mo.
As indicated previously, GonaCon-treated
white-tailed deer showed a reduced number of
estrus cycles or did not cycle at all, an effect
probably due to the lack of estrogen. This reduced
breeding behavior associated with infertility was
typically seen during the first few years following
vaccination. Although the single injection of
GonaCon induced infertility for multiple years,
an occasional return to breeding behavior 4–5 yr
after vaccination, prior to the return of fertility
(Miller, unpubl. data),42 was observed. This return
of breeding behavior prior to the return of fertility
has also been observed in wild horses (Gray,
unpubl. data)18 and in wild boar (Sus scrofa).37 It is
speculated that the reason for the return of
breeding behavior prior to the return of fertility
could be that GonaCon controls LH levels more
completely than it controls levels of FSH. As the
level of GnRH antibodies drops in immunized
animals over several years, sufficient gonadotro-
pins are released to allow estrogen to reach levels
that can induce signs of estrus, but GnRH is still
sufficiently inhibited to block the LH surge and
ovulation. As the GnRH antibody titer drops
further, more LH is released, ovulation resumes
and the animal can become pregnant. A vaccine
boost will enhance the longevity of the vaccine’s
efficacy in both males and females. Male white-
tailed deer were given a boost of GonaCon that
lengthened the time that they remained infertile
by several years.29 In a study with female bison
(Bison bison) at the Northwest Trek Zoo in 2001
(Eatonville,Washington, 98328, USA), a prime
dose was effective in contracepting three of five
bison; however, a boost given 1 yr later rendered
all bison infertile the second year, and they
remained infertile for at least 3 yr.58 Untreated
bison in the herd calved normally.
The authors’ research has also demonstrated
the importance of timing when injecting the
vaccine. The vaccine is most effective if given at
least a month or more before the onset of
reproductive activity. This allows time for an
adequate titer level to develop so contraception
can occur.42
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UNDERSTANDING THE SINGLE
INJECTION PRINCIPLE
There are very few vaccines on the market that
are effective with a single injection, so the
statement that GonaCon is effective in contra-
cepting animals with a single injection is often
received with skepticism, especially from knowl-
edgeable immunologists. GonaCon is effective as
a single injection due to three primary factors: 1)
the GnRH antigen is coupled to a large foreign
molecule in a systematic manner; 2) the vaccine
antigen is made into a stable emulsion; and 3) M.
avium is included in the adjuvant.
GnRH is a small peptide hormone that is a
weak antigen due to its low molecular weight and
its being a ‘‘self’’ hormone. However, due to its
small size, GnRH can easily be made synthetical-
ly. In the GonaCon vaccine, GnRH is made
immunogenic by ensuring that each synthetic
GnRH peptide molecule is conjugated in a very
systematic and predictable manner to a large,
nonself, highly immunogenic hemocyanin protein
harvested from marine mollusks;51,52 thus produc-
ing a GnRH-mollusk protein conjugate. Many
pathogens, including viruses and bacteria, exhibit
rigid, highly organized, and highly repetitive
surface protein epitopes. The GonaCon design
provides a consistent alignment of up to 300
GnRH peptide molecules on the surface of the
large mollusk protein, mimicking the repetitive
nature of pathogen epitopes, an important aspect
of the GnRH-hemocyanin conjugate design. The
original mollusk protein used was KLH. Howev-
er, the high price of KLH (now used in cancer
therapy vaccines) prompted a search for a more
economical hemocyanin carrier protein for the
GnRH peptide. Blue protein, derived from the
mollusk Concholepas concholepas, proved to be a
successful option. The single injection blue pro-
tein formulation has been shown to provide a
longer-lasting effect compared with the KLH
preparation in white-tailed deer.39,42
This water-soluble GnRH/mollusk conjugate is
then made into a water-in-oil emulsion with the
adjuvant AdjuVac. The mineral oil-based emul-
sion provides a depot effect for the vaccine and
protects the antigen from rapid destruction by the
macrophages of the target animals’ immune
system.39 This provides for a strong prolonged
immune response because of the slow release rate
of the GnRH conjugate antigen at the injection
site. Remnants of vaccine have been observed at
the injection site during necropsy up to 2 yr after
vaccination (unpubl. obs.). A water-in-oil emul-
sion appears to be the only formulation that
provides a long-term contraceptive response in
both PZP and GnRH vaccines with a single
injection.
In all of the successful immunocontraceptive
vaccine studies, adjuvants have been used as part
of the immunocontraceptive vaccine to enhance
the immune response of the host animal to the
PZP or GnRH antigen. Adjuvants for contracep-
tive vaccines are critical in providing efficacy, but
unfortunately, the immunostimulatory properties
of some of the most effective adjuvants can result
in localized inflammation and tissue destruction.1
In initial research on white-tailed deer, the PZP
used by the NWRC was formulated as an
emulsion with Freund’s Complete Adjuvant for
the first injection and Freund’s Incomplete Adju-
vant for subsequent boosts. During discussions
with the Food and Drug Administration (FDA)
regarding the potential for gaining regulatory
approval of immunocontraceptives, the FDA
stated their opposition to the use of any vaccine
containing Freund’s adjuvant because of its
known inflammatory effects. The NWRC began
work on a safer adjuvant in 1998, leading to
development of a new oil-based adjuvant called
AdjuVac, which for currently registered uses
contains ,200 lg of killed M. avium per 1-ml
dose. Inflammatory reactions caused by AdjuVac
are less severe than those caused by Freund’s
complete adjuvant.2,57, AdjuVac has been used as
the adjuvant for both PZP and GnRH vaccines by
the NWRC since 1998.
In addition to the stable emulsion, the long-
lasting contraceptive effect of GonaCon is depen-
dent on the presence of M. avium in the adjuvant.
In early NWRC studies with PZP immunocon-
traceptive vaccines in deer using Freund’s adju-
vant, it was necessary to boost with incomplete
Freund’s at least once, and sometimes several
times, to maintain high antibody titers. When it
was switched to the new adjuvant AdjuVac, which
contains killedM. avium, it was found that in most
animals (e.g., deer,42 horses,24 and prairie dogs
[Cynomys ludovicianus]66) a boost was not needed
to achieve a long-lasting immune response. My-
cobacterium avium has been shown to be ubiqui-
tous in nature,10 having been recovered from
almost every environmental compartment that
has been investigated, including fresh water,
brackish water, biofilms, aerosols, soils, food
plants, plant products, and fish. Furthermore,
isolation from a hospital water system over a
period of 18 mo demonstrated that M. avium is
commonly found in drinking-water because of its
high resistance to ozone and chlorine-based
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disinfectants.31 The authors hypothesize that due
to the ubiquitous nature of M. avium, it is a key
factor in the success of GonaCon.39,42,55 Most
animals will have previously experienced and
produced an immune response to M. avium;
therefore, the immune system is already primed,
leading to a more immediate response to the
vaccine than would normally be expected after
only a single dose.
Current research from the authors’ laboratory
has shown that a single injection of Gonacon can
provide a multiyear contraceptive effect and has
also shown that prolonged infertility with Gona-
Con is directly related to high serum concentra-
tion of GnRH antibodies.42 Burton et al.4 writes,
‘‘To be effective in producing long-lasting anti-
bodies, antigen administered in a single dose must
be retained in the body long enough to produce
specific antibodies that will bind with the antigen
to form immune complexes (ICs).’’ Fukanoki et
al.11,12 demonstrated in chickens that the slow
release of antigen from oil-based emulsions was
positively correlated to immune response. A slow
antigen release allows ICs to form, creating a
greater immune response. These ICs can then
bind to follicular dendritic cells (FDCs) that
protect the antigen from macrophage and liver
degradation. ICs may begin to form within 7–14
days after a primary injection or within minutes
after a booster. The FDCs can provide the
continued presence of antigen for months to
years.36 Antigen release from the FDCs relates to
the level of the antigen-specific antibody. When
specific antibody levels drop, the FDCs will
release the specific antigen, boosting the circulat-
ing antibody.41 It is believed that the carefully
prepared emulsion used in GonaCon serves as a
depot, allowing retention and slow release of the
target antigen (i.e., GnRH).
USE OF GONACON FOR REPRODUCTIVE,
BEHAVIOR, ANDDISEASEMANAGEMENT
GonaCon was initially developed as a manage-
ment tool for urban/suburban populations of the
ever-expanding white-tail deer populations that
can be used when other management tools, such
as hunting, are impractical or not legal. However,
it soon became apparent that a GnRH-based
contraceptive could apply to other species as well.
Because GnRH is common to all mammals, the
GonaCon immunocontraceptive vaccine has in-
duced contraception in many overabundant mam-
malian species, including white-tailed deer,47 elk
(Cervus elaphus),22 wild horses,24,25,18 bison,50 Cal-
ifornia ground squirrels (Spermophilus beecheyi),53
prairie dogs,66, gray squirrels (Sciurus carolinen-
sis),54,65 captive Norway rats (Rattus norvegicus),44
domestic and feral swine and wild boar,26,27,51,37
brushtail possums (Trichosurus vulpecula),8 and
tammar wallabies (Macropus eugenii).59 In the
United States, all of these uses in wildlife will be
regulated by the Environmental Protection Agen-
cy.
GonaCon is also being tested as a technique to
assist in control of feral or wild dogs and in
management of rabies. Rabies in domestic dogs
(Canis familiaris) has been eliminated in most of
the developed world through extensive vaccina-
tion, and now rabies only persists in wildlife in
these areas.64 However, in the developing world
and in poverty-stricken areas, domestic dogs
remain the principle vectors of rabies, with dog
bites contributing to more than 95% of human
rabies cases.5 Effective rabies control relies on a
combination of large-scale vaccination as well as
effective dog population control strategies. Most
population control programs have moved away
from culling of animals toward surgical steriliza-
tion, which is expensive, labor intensive, and does
not always reach enough of the dog population to
be effective. GonaCon is being investigated as a
tool to provide contraception of dogs through a
single injection that can be administered in
conjunction with a rabies vaccine during annual
vaccination campaigns. Simultaneous injection of
GonaCon with a canine rabies vaccine in dogs did
not affect the development of rabies antibodies.2
Further research is being conducted to determine
the effectiveness of combined contraceptive and
rabies vaccine programs as a rabies control tool in
field situations.
GonaCon has also been tested in zoo animals,
livestock, and companion animals for situations
in which animals are not intended to be bred. It
has induced contraception in domestic cats,32,33
and domestic swine.26,27 GonaCon has also been
proposed as a technique for eliminating unwanted
behaviors associated with reproduction in com-
panion or work animals. However, because the
current GonaCon formulation is designed to last
for several years, which may not be desirable in
certain situations, the formulation would need to
be redesigned to last only a few months to a year
as needed. Regardless, uses of GonaCon in
domestic or zoo animals would be regulated by
the FDA’s Center for Veterinary Medicine; these
uses will not be pursued by the NWRC but could
be pursued by collaborators.
Contraception with GonaCon offers potential
as a disease management tool for certain diseases,
S90 JOURNAL OF ZOO AND WILDLIFE MEDICINE
most notably, venereally transmitted diseases or
diseases transmitted at parturition, such as bru-
cellosis. Swine brucellosis is transmitted through
the venereal route as well as through contact with
aborted fetuses and placental membranes and
fluids. Bovine brucellosis is transmitted among
cattle (Bos taurus), bison, and elk, primarily
through contact with infected aborted fetuses
and placentas and to calves from infected milk.58
GonaCon has been and is currently being tested
to prevent parturition in bison. Studies in bison
showed that a single dose of the vaccine resulted
in infertility in all vaccinates for multiple years.50
If ongoing studies demonstrate GonaCon’s utility
in decreasing shedding of Brucella abortus, the
vaccine could provide a potential nonlethal man-
agement tool to prevent transmission of the
disease in an infected population.
GonaCon has been tested as a tool for the
treatment and prevention of adrenal cortical
disease (ACD) in domestic ferrets.40 ACD is a
common problem in neutered middle-aged and
older ferrets, affecting the majority of animals by
7 yr of age, often causing alopecia, adrenal
hyperplasia, and tumors. ACD is caused by the
excessive continuous production of LH due to the
lack of negative feedback from gonadal hormones
in neutered ferrets, resulting in overproduction of
sex steroids by the adrenal glands. Injection with
GonaCon reduces the production of LH, and thus
the adrenal sex hormones, thereby reducing ACD
and its clinical signs. In an ongoing study, 88
neutered young male and female ferrets were
vaccinated with GonaCon.40 Only 25% of treated
ferrets developed clinical signs of ACD by 8 yr of
age compared with 84% of control ferrets, indi-
cating that GonaCon may offer a therapeutic tool
for the prevention of ACD in ferrets.
SAFETYAND TOXICITY OF GONACON
The NWRC has conducted several studies that
have shown that GonaCon can reduce fertility in
deer for multiple years without any obvious side
effects other than injection site reactions visible
upon necropsy. GonaCon is currently registered
with the Environmental Protection Agency (EPA)
for use in white-tailed deer and in wild horses and
burros (GonaCon-Equine). A safety study was
designed to evaluate the potential for negative
health effects if deer accidentally received multi-
ple injections of GonaCon.21 In the study, seven
does were given a single injection of GonaCon
(EPA-registered formulation) and another six
does were given three injections at 2-wk intervals.
Both groups were compared with a saline control
group (n ¼ 6). Blood samples were drawn period-
ically, and the deer were observed for general
health. At 20 wk, the deer were euthanized,
necropsies were conducted, and the blood was
tested using hematology and chemistry health
profiles. Aside from some granulomata formation
seen at necropsy in the muscle at the injection
site, typically evidenced by a tan-yellow appear-
ance and a bulge at the cut surface, there were no
toxic or health effects associated either with
GonaCon given in a single injection or in multiple
injections.
Another potential concern addressed by the
NWRC was the health of animals when injected
with GonaCon while pregnant. The mechanisms
required for the maintenance of pregnancy differ
between species; however, in all mammalian
species progesterone, from the corpus luteum
and or placenta, is required at some stage. In
many years of using GonaCon in white-tailed
deer, no indications of abortions after treatment
were noted; however, to test this, GonaCon was
injected into six deer that tested positive for
pregnancy by ultrasound in the first week of
February. All deer gave birth to healthy fawns
but were then infertile for 2 to 3 yr.43 Other
animals have also been injected with GonaCon
while pregnant, including elk, bison, and wild
horses;56,50,28 all delivered normal offspring the
next year and then were infertile in the following
years. Thus, in species tested to date, GonaCon is
safe for use in pregnant animals.
Research was also conducted to determine the
effect of using GonaCon on white-tailed deer
fawns, because it is sometimes difficult to tell a
fawn from a doe in the late summer through
winter, when darting with an immunocontracep-
tive vaccine could occur.43 To determine the
effects on fawns, six male and six female fawns
were given two injections of 450 lg of GonaCon 1
mo apart at 3 and 4 mo of age, in September and
October. All fawns developed initial elevated
titers to GnRH; however, the GnRH antibody
titers in 11/12 fawns dropped by the following
fall, and those fawns came into breeding condi-
tion. Only one female retained a high antibody
titer and remained infertile throughout the 3-yr
study.43
Another of the concerns with using an immu-
nocontraceptive vaccine is the occurrence of
injection site reactions. Successful stimulation of
the immune system requires some level of injec-
tion site reaction because the injection site
represents the area where the animals’ immune
system sees and attacks the invading foreign
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material, creating an immune response. As dis-
cussed, vaccines that are able to remain at the
injection site, without being destroyed, can pro-
vide a long-lasting immune response. Injection
site reactions vary among vaccine formulations,
species, and animals. For example, vaccines
containing mineral oil-based adjuvants produce
more frequent injection site reactions because of
the vaccine emulsion remaining at the injection
site. If the vaccine is not cleared from the
injection site area, the body walls this area off,
forming a granuloma. In some cases, more severe
reactions occur that result in open sores or
draining abscesses.
There are large differences among species in
susceptibility to injection site reactions. Some
species, including cats,32 wallabies,60 and grey
kangaroos (Macropus giganteus),60 appear to be
less prone to injection site reactions than others
after treatment with GonaCon. After a single
GonaCon injection, Levy reported no injection
site reactions in female cats during the first 2 yr of
a study; at 2 yr, the appearance of a nonpainful but
persistent late-onset injection site mass was
reported in some animals.32 Lyn Hinds (pers.
comm.) also noticed no initial injection site
reactions in grey kangaroos or wallabies but
observed in some wallabies late-onset nonpainful
injection masses (up to 2 cm wide) that would
come and go over a period of months in the
GonaCon injection site.
In contrast, dogs (n¼ 3) treated with GonaCon
(registered formulation; Table 1) experienced
severe injection site reactions.19 This may be
due to general differences between species, with
dogs being more susceptible to these types of
reactions. It is suspect that the amount of M.
avium in the vaccine is, at least in part, respon-
sible for the injection site reactions in dogs. In a
subsequent trial, dogs (n ¼ 12) were treated with
GonaCon that contained half the amount of M.
avium than was previously tested. Dogs still
experienced injection site reactions, but they
were less severe (S. Bender, pers. comm.). A
third trial was conducted in Mexico, where dogs
were treated using only one-fourth of the M.
avium.63 No severe injection site reactions oc-
curred, and there were no signs of pain or
limping in the dogs because of vaccination. At
necropsy, there was evidence of gross and
microscopic lesions in muscle tissue, but reac-
tions were much reduced compared with previ-
ous trials. Additional trials are ongoing with
GonaCon-Canine, a formulation with the re-
duced M. avium concentration.
In the authors’ studies, injection site reactions
have occurred more frequently in field trials than
in pen trials with white-tailed deer.13,14 During the
19 yr of vaccinating deer housed in Penn State
University pens, there were no visible injection
site reactions in any of the deer, and necropsies
following the studies did not show any remark-
able injection site reaction. These Penn State
deer were fed a high-quality diet and were
medicated three times a year to ensure they were
parasite free. Because of the complete lack of
injection site reactions, it was a surprising that
some of the deer in the field studies13,14 developed
injection site reactions that were visible upon
necropsy. The deer were in poor health because
of overpopulation of the deer herd, and at
necropsy we found the deer were infested with
many parasites. It is possible that poor general
health and/or high parasite load may be corre-
lated with an increase in injection site reactions,
but further research is necessary to explain the
mechanism behind the differences seen.15
Similarly, contraceptive efficacy of GonaCon
was consistently higher in captive than in free-
ranging white-tailed deer and feral horses.13,14,18 It
was hypothesized that parasites in the free-
ranging study animals may have reduced their
hosts’ immune responses to vaccination with
GonaCon. Captive animals in these trials re-
ceived optimal nutrition and regular veterinary
care, including routine deworming, whereas free-
ranging wild deer and horses received no veter-
inary intervention. Similar variation in vaccine
efficacy has been observed in humans, where
several vaccines used in infants failed to confer
the expected protection in heavily helminth-
parasitized populations but were highly effica-
cious in populations in which parasitism was
uncommon.15 Abundant experimental evidence
from studies in humans and animal models
indicates that parasitic helminths can suppress
or divert host immune responses and reduce
vaccine efficacy. Therefore, inferences on effec-
tiveness of a contraceptive vaccine based on pen
studies may be overly optimistic.
DEVELOPING A PHARMACEUTICAL-
GRADE VACCINE
To move from a benchtop experimental vaccine
to one that could be registered by the EPA and
potentially licensed to a manufacturer, the
NWRC needed to make changes in some of the
GonaCon vaccine inert ingredients and the man-
ufacturing process. Changes included using high-
er-quality mineral oil and surfactant, moving the
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manufacturing process from a chemistry bench-
top to a clean room, and developing an aseptic
manufacturing technique to deliver a sterile
vaccine product.
For GonaCon to be mass-produced for sale, the
need for a more efficient and economical produc-
tion system is needed. Several steps have been
made to produce larger GonaCon batches, reduce
the cost of reagents, and reduce the time involved
in the manufacturing process. Production of
GonaCon requires the proper conjugation of
GnRH peptides to a mollusk carrier protein and
the preparation of a stable water-in-oil emulsion
of the GnRH conjugate with the AdjuVac adju-
vant. The authors’ were able to shorten the time
required to make the GnRH conjugate and the
amount of reagents used. This allowed the
production of a quality emulsion by using a
commercial emulsifier machine (Microfluidics,
Newtown, Massachusetts, 02464, USA). This
helps to reduce variability between batches and
allows for the vaccine to be preloaded in syringes,
thus eliminating the need to mix vaccines in the
field. Quality control steps have been added to the
manufacturing process for GonaCon, including a
determination of the amount of the active ingre-
dient, the GnRH peptide, in the GonaCon
vaccine.16 Determination of the stability of the
active ingredient is required by the EPA for the
GonaCon registration, so the chemistry section of
the NWRC developed an analytical method to
determine the amount of the active ingredient in
GonaCon; this method was used to perform a
vaccine stability study. In addition to the chemis-
try analytical method, a biologic assay in rabbits
was used to determine efficacy of the GonaCon
vaccine. These studies have allowed for a 6-mo
shelf life on the outgoing GonaCon vaccine when
it is stored and shipped at 48C.
SUMMARYAND FUTURE DIRECTIONS
FOR NWRC REPRODUCTIVE CONTROL
RESEARCH
During the 20 yr that the NWRC has been
conducting research on immunocontraceptives,
the NWRC has had successes and failures and has
learned some important general lessons. Both
PZP and GnRH antigens can be effective antigens
for immunocontraceptive vaccines in many spe-
cies. Each of these products has advantages and
disadvantages, and its use needs to be based on
evaluation of the wildlife problem to be solved.
The effectiveness of the vaccines is dependent on
their formulation and on the proper presentation
of the target antigen. The vaccines require a
powerful adjuvant and a water-in-oil emulsion to
be most effective. The presence of a ubiquitous
Mycobacterium (killed) in the adjuvant enhances
vaccine efficacy.
When used in combination with AdjuVac,
SpayVac (a PZP vaccine), and GonaCon (a GnRH
vaccine), formulations can provide single injec-
tion, multiple year effectiveness. A boost vacci-
nation can extend the effectiveness of the
vaccines, sometimes making the animal perma-
nently infertile, but the effectiveness of vaccines
varies between species and among individuals. A
certain proportion of animals will be nonrespond-
ers and will not generate a high antibody titer.
Vaccines are most effective if injected at least a
month or more before the onset of reproductive
activity to allow time for antibody development.
Field efficacy of a vaccine may be lessened by high
parasite load and poor body condition. Localized,
nonpainful injection site reactions caused by the
long-term presence of the vaccine can occur but
may be part of the process of developing a long-
lasting antibody response after a single injection.
Animals treated with either PZP or GonaCon
vaccines can be consumed because the protein
antigens are broken down into amino acids in the
gastrointestinal tract.
In addition to these general lessons, the NWRC
has gained considerable insight into PZP vac-
cines. For example, the native PZP was shown to
be much more antigenic than peptides or recom-
binant proteins. Also, PZP vaccines are not
effective in all mammalian species.17 PZP vaccines
may cause undesirable behavioral effects such as
multiestrus.
During its development and testing, the NWRC
has observed that GonaCon is effective in most
mammalian species, with contraceptive effects
lasting longer in females than in males. GonaCon
can be safely given to pregnant animals without
interfering with the pregnancy. GonaCon can
eliminate almost all reproductive behaviors, in-
cluding estrus cycles and theoretically some
undesirable behaviors in companion animals. It
may also provide a potential management tool for
venereally transmitted diseases or diseases trans-
mitted at parturition. GonaCon can effectively
prevent ACD in domestic ferrets by reducing LH
levels. However, approval for use of GonaCon in
companion animals or for disease prevention will
be through regulatory agencies other than the
EPA and will not be pursued by the Animal Plant
Health Infection Service.
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Future research at the NWRC will continue to
look for new applications for the use of GonaCon
and will continue research into understanding the
immunology behind the variations in effective-
ness from species to species. It is hoped that
information on the timeframe in which to give a
boost to improve the length of the contraceptive
response can be developed. The NWRC also
hopes to pursue studies on its effective use as a
management tool and to develop private sources
of manufacturing for GonaCon in efforts to
commercialize the product and make it more
widely available.
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